Skip to main content
SCYNEXIS INC logo

SCYNEXIS INC — Investor Relations & Filings

Ticker · SCYX ISIN · US8112922005 LEI · 529900XBHFGMNTU70154 US Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2015-01-06 Director's Dealing
Country US United States of America
Listing US SCYX

About SCYNEXIS INC

https://www.scynexis.com/

SCYNEXIS, Inc. is a biotechnology company focused on the discovery and development of novel anti-infectives to overcome difficult-to-treat and drug-resistant fungal infections. The company is pioneering a new class of broad-spectrum antifungal agents called 'fungerps,' which are triterpenoid-based compounds. These agents are being developed in both oral and intravenous formulations to treat a range of serious, invasive, and life-threatening fungal diseases, particularly those encountered in hospital environments. SCYNEXIS aims to address the significant global health threat of antifungal resistance by providing innovative therapeutic options where existing treatments are limited or ineffective. The company's development pipeline includes second-generation fungerp candidates.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2015-01-06 English
FORM 4
Director's Dealing
2015-01-06 English
FORM 4
Director's Dealing
2015-01-06 English
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC. Form S-8 is used to register securities to be offered under employee benefit plans, such as equity incentive plans. The document includes details about the registration of additional shares under the SCYNEXIS, Inc. 2014 Equity Incentive Plan, exhibits related to corporate governance documents, legal opinions, and consents. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration and compliance with the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS).
2014-12-18 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an amendment to a material definitive agreement between SCYNEXIS, Inc. and Merck, specifically about deferring and adjusting milestone payments under a licensing agreement. There are no financial statements or detailed financial performance data, nor is this an earnings release or annual/interim report. It is not a proxy, voting result, or management change announcement. The document is a regulatory filing reporting a material contract amendment, which fits best under the category of Regulatory Filings (RNS). The document length is 2672 characters, which is short and typical for an 8-K filing. Therefore, the classification is RNS with high confidence.
2014-12-17 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, specifically under Item 5.02 which relates to the departure of directors or certain officers. The text details the resignation of an officer, Eileen C. Pruette, from her position as General Counsel effective December 31, 2014. There is no financial data, earnings information, or other report content. The document is an announcement of a management change, fitting the category of Board/Management Information (MANG). The document length is short (2240 characters), consistent with a typical 8-K filing for management changes. Therefore, the correct classification is MANG with high confidence.
2014-12-08 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.